THE ROLE OF CERVICOVAGINAL MICROBIOME HOMEOSTASIS IN THE EARLY DIAGNOSIS AND MANAGEMENT OF PELVIC INFLAMMATORY DISEASE
Abstract
Pelvic inflammatory disease (PID) is a major cause of reproductive morbidity and is traditionally linked to sexually transmitted pathogens, particularly Chlamydia trachomatis and Neisseria gonorrhoeae. However, growing evidence indicates that disruption of cervicovaginal microbiome homeostasis also plays a central role in the pathogenesis, progression, and persistence of PID. Objective: To review current evidence on the role of cervicovaginal microbiome homeostasis in the early diagnosis and management of PID, with emphasis on mechanisms of dysbiosis, microbiome-based diagnostic markers, and emerging restoration-focused therapeutic strategies. Methods: This narrative review synthesizes recent literature addressing cervicovaginal microbiome composition, vaginal eubiosis and dysbiosis, bacterial vaginosis-associated microbial shifts, microbial predictors of upper genital tract spread, and microbiome-informed interventions relevant to PID. Results: Available evidence indicates that a stable cervicovaginal microbiome, typically characterized by Lactobacillus dominance, supports mucosal barrier integrity, acidic vaginal pH, and colonization resistance. In contrast, dysbiosis is associated with anaerobic overgrowth, biofilm formation, inflammatory activation, and increased risk of ascending infection. Reduced abundance of protective taxa, particularly Lactobacillus crispatus, and specific microbial signatures have emerged as promising biomarkers for early PID risk stratification and detection of subclinical disease. In parallel, microbiome-informed management strategies, including probiotics, ecological restoration approaches, and dietary modulation through the gut-vagina axis, have shown potential as adjuncts to conventional antimicrobial therapy. Nevertheless, current evidence remains heterogeneous, and clinical application is limited by variation in study design, sampling methods, and biomarker validation. Conclusion: Cervicovaginal microbiome homeostasis is increasingly recognized as a key determinant of susceptibility to PID and a promising target for earlier diagnosis and improved management.
References
1. Luu LDW, Bryant C, Brown J, Turner M, Pham TH, Mazraani R, et al. Cervicovaginal microbiome composition and absolute quantity are associated with pelvic inflammatory disease. Microb Genom. 2025;11:001574. doi:10.1099/mgen.0.001574.
2. Schettini G, Pieri E, Rizzo C, Giorgi M, Mancini V, Habib N, et al. A dive into the invisible: the vaginal and endometrial microbiota in gynecologic and obstetric disorders: a narrative review. Life. 2026;16:762. doi:10.3390/life16020762.
3. Sweeney S, Bateson D, Fleming K, Huston WM. Factors associated with pelvic inflammatory disease: a case series analysis of family planning clinic data. Womens Health. 2022;18:1-6. doi:10.1177/17455057221112263.
4. Rodrigues R, Silva AR, Sousa C, Vale N. Disrupted cervicovaginal microbiota: its role in Chlamydia trachomatis genital infection and associated reproductive outcomes. Int J Mol Sci. 2025;26:10635. doi:10.3390/ijms262110635.
5. Borrego-Ruiz A, Borrego JJ. Determinants of vaginal microbiome stability and homeostasis. Biocell. 2025;49(8):1313-1332. doi:10.32604/biocell.2024.052601.
6. Aldunate M, Srbinovski D, Hearps AC, Latham CF, Ramsland PA, Gugasyan R, et al. Antimicrobial and immune modulatory effects of lactic acid and short chain fatty acids produced by vaginal microbiota associated with eubiosis and bacterial vaginosis. Front Physiol. 2015;6:164. doi:10.3389/fphys.2015.00164.
7. Jeong S, Tollison T, Brochu H, Zheng X, O'Connell CM, Peng X. Cervicovaginal microbial features predict Chlamydia trachomatis spread to the upper genital tract of women. Infect Immun. 2025;12 Aug 2025:1-20. doi:10.1128/iai.00057-25.
8. Abbe C, Mitchell CM. Bacterial vaginosis: a review of approaches to treatment and prevention. Front Reprod Health. 2023;5:1100029. doi:10.3389/frph.2023.1100029.
9. Liu D, Zhang X, Zhao X, Che X, Song W, Wu G. Bacterial vaginosis: advancing insights into microbial dysbiosis. Crit Rev Microbiol. 2026;52(1):159-175. doi:10.1080/1040841X.2025.2537923.
10. Kim S, Seo H, Rahim MA, Tajdozian H, Kim YS, Song HY. Characteristics of vaginal microbiome in women with pelvic inflammatory disease in Korea. Pol J Microbiol. 2021;70(3):345-357. doi:10.33073/pjm-2021-033.
11. Lee CY, Bonakdar S, Arnold KB. An in silico framework for the rational design of vaginal probiotic therapy. PLoS Comput Biol. 2025;21(2):e1012064. doi:10.1371/journal.pcbi.1012064.
12. Wang Y, Liu Z, Chen T. Vaginal microbiota: potential targets for vulvovaginal candidiasis infection. Heliyon. 2024;10:e27239. doi:10.1016/j.heliyon.2024.e27239.
13. Jin H, Niu Z, Zhao X. The association between dietary fiber intake and pelvic inflammatory disease in women: findings from the NHANES 2015-2018. BMC Womens Health. 2025;25:356. doi:10.1186/s12905-025-03911-z.
14. Bao Y, Hu X, Gao T, Hua W. Association between dietary index for gut microbiota and the risk of pelvic inflammatory disease: mediating role of anti- and pro-inflammatory dietary patterns. Food Sci Nutr. 2026;14:1-11. doi:10.1002/fsn3.71563.
15. Usyk M, Carlson L, Schlecht NF, Sollecito CC, Grassi E, et al. Cervicovaginal microbiome and natural history of Chlamydia trachomatis in adolescents and young women. Cell. 2025;188:1051-1061. doi:10.1016/j.cell.2024.12.011.
16. van de Wijgert JHHM. The vaginal microbiome and sexually transmitted infections are interlinked: consequences for treatment and prevention. PLoS Med. 2017;14(12):e1002478. doi:10.1371/journal.pmed.1002478.
17. Filardo S, Di Pietro M, Porpora MG, Recine N, Farcomeni A, Latino MA, et al. Diversity of cervical microbiota in asymptomatic Chlamydia trachomatis genital infection: a pilot study. Front Cell Infect Microbiol. 2017;7:321. doi:10.3389/fcimb.2017.00321.
18. Filardo S, Di Pietro M, Tranquilli G, Latino MA, Recine N, Porpora MG, et al. Selected immunological mediators and cervical microbial signatures in women with Chlamydia trachomatis infection. mSystems. 2019;4:e00094-19. doi:10.1128/mSystems.00094-19.
19. Chen X, Lu Y, Chen T, Li R. The female vaginal microbiome in health and bacterial vaginosis. Front Cell Infect Microbiol. 2021;11:631972. doi:10.3389/fcimb.2021.631972.
20. Chen H, Wang L, Zhao L, Luo L, Min S, Wen Y, et al. Alterations of vaginal microbiota in women with infertility and Chlamydia trachomatis infection. Front Cell Infect Microbiol. 2021;11:698840. doi:10.3389/fcimb.2021.698840.
21. Onderdonk AB, Delaney ML, Fichorova RN. The human microbiome during bacterial vaginosis. Clin Microbiol Rev. 2016;29:223-238. doi:10.1128/CMR.00075-15.
22. Vitale SG, Carugno J, D’Alterio MN, Mikuš M, Patrizio P, Angioni S. A new methodology to assess fallopian tubes microbiota and its impact on female fertility. Diagnostics. 2022;12:1375. doi:10.3390/diagnostics12061375.
23. Cagnacci A, Londero AP, Scovazzi U, Xholli A. A role of the uterine cervix in the pathogenesis of adenomyosis and endometriosis? Int J Gynecol Obstet. 2025;171:1128-1134. doi:10.1002/ijgo.70287.
24. Mizgier M, Jarząbek-Bielecka G, Mruczyk K, Kędzia W. The role of diet and probiotics in prevention and treatment of bacterial vaginosis and vulvovaginal candidiasis in women. Ginekol Pol. 2020;91(7):412-416. doi:10.5603/GP.2020.0070.
25. Kobayashi H. Similarities in pathogenetic mechanisms underlying the bidirectional relationship between endometriosis and pelvic inflammatory disease. Diagnostics. 2023;13:868. doi:10.3390/diagnostics13050868.
26. Liu P, Lu Y, Li R, Chen X. Use of probiotic lactobacilli in the treatment of vaginal infections: in vitro and in vivo investigations. Front Cell Infect Microbiol. 2023;13:1153894. doi:10.3389/fcimb.2023.1153894.
27. Kerry-Barnard S, Zhou L, Phillips L, Furegato M, Witney AA, Sadiq ST, et al. Vaginal microbiota in ethnically diverse young women who did or did not develop pelvic inflammatory disease: community-based prospective study. Sex Transm Infect. 2022;98:503-509. doi:10.1136/sextrans-2021-055260.
28. Dumonceaux TJ, Schellenberg J, Goleski V, Hill JE, Jaoko W, Kimani J, et al. Multiplex detection of bacteria associated with normal microbiota and with bacterial vaginosis in vaginal swabs by use of oligonucleotide-coupled fluorescent microspheres. J Clin Microbiol. 2009;47(12):4067-77. doi:10.1128/JCM.00112-09.
29. Xiao B, Chen C, Liao Q, et al. Predictive value of the composition of the vaginal microbiota in bacterial vaginosis, a dynamic study to identify recurrence-related flora. Sci Rep. 2016;6:26674. doi:10.1038/srep26674.
30. Barrientos-Durán A, Fuentes-López A, de Salazar A, Plaza-Díaz J, García F. Reviewing the composition of vaginal microbiota: inclusion of nutrition and probiotic factors in the maintenance of eubiosis. Nutrients. 2020;12:419. doi:10.3390/nu12020419.
31. Danusevich IN, Sharifulin EM, Nemchenko UM, Kolesnikova LI. Features of the immune system functioning with persistence of infectious agents in women with chronic endometrial inflammation and reproductive disorders. Int J Biomed. 2020;10(4):362-368. doi:10.21103/Article10(4)_OA6.
32. Miao R, Badger TC, Groesch K, Diaz-Sylvester PL, Wilson T, Ghareeb A, et al. Assessment of peritoneal microbial features and tumor marker levels as potential diagnostic tools for ovarian cancer. PLoS One. 2020;15(1):e0227707. doi:10.1371/journal.pone.0227707.
33. Choi SY, Choi JH. Ovarian cancer and the microbiome: connecting the dots for early diagnosis and therapeutic innovation. Medicina. 2024;60:516. doi:10.3390/medicina60040516.
34. Semertzidou A, Bennett PR, Lee YS, Marchesi JR, Smith A, Cacciatore S, et al. Microbial signatures and continuum in endometrial cancer and benign patients. Microbiome. 2024;12:118. doi:10.1186/s40168-024-01821-0.
35. Tai FW, Chang CY, Hsu YA, Chiang JH, Wan L, Lin WC. Association of pelvic inflammatory disease with risk of endometriosis: a nationwide cohort study involving 141,460 individuals. Taiwan J Obstet Gynecol. 2018;57:829-832. doi:10.1016/j.tjog.2018.10.011.
36. Tamarelle J, Thiébaut ACM, de Barbeyrac B, Bébéar C, Ravel J, Delarocque-Astagneau E. The vaginal microbiota and its association with human papillomavirus, Chlamydia trachomatis, Neisseria gonorrhoeae and Mycoplasma genitalium infections: a systematic review and meta-analysis. Clin Microbiol Infect. 2019;25:35-47. doi:10.1016/j.cmi.2018.04.019.
37. van de Wijgert JHHM, Verwijs MC, Gill AC, Borgdorff H, van der Veer C, Mayaud P. Pathobionts in the vaginal microbiota: individual participant data meta-analysis of three sequencing studies. Front Cell Infect Microbiol. 2020;10:129. doi:10.3389/fcimb.2020.00129.
38. Chukwu EE, Abuh D, Idigbe IE, Omoregha P, Okwuraiwe AP, et al. Prevalence and associated risk factors of bacterial vaginosis among women of reproductive age living with, and without HIV in Lagos, Nigeria. BMC Womens Health. 2025;25:460. doi:10.1186/s12905-025-04024-3.
39. Holdcroft AM, Ireland DJ, Payne MS. The vaginal microbiome in health and disease-what role do common intimate hygiene practices play? Microorganisms. 2023;11:298. doi:10.3390/microorganisms11020298.
40. Capozzi VA, Incognito GG, Scarpelli E, Palumbo M, Randazzo CL, Pino A, et al. Exploring the relationship between ovarian cancer and genital microbiota: a systematic review and meta-analysis. J Pers Med. 2024;14:351. doi:10.3390/jpm14040351.
